← Back

Wire · opportunities

Nelkarmi wins FDA accelerated approval for ALK-positive lung cancer after alectinib or ...

Published

18 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at medicaldaily.com →

◆ Verified

Fusion42 · 18 November 2026 · Fusion42 review

The FDA granted accelerated approval to Nelkarmi (neladalkib) for adults with advanced ALK-positive non-small cell lung cancer after progression on alectinib or multiple prior ALK inhibitors and chemotherapy, based on tumor response rates from a Phase 1/2 trial. The approval provides an additional targeted treatment option for this patient subgroup, though ongoing confirmatory trials are required to verify long-term clinical benefit.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your drug targeting ALK-positive lung cancer gains US market access faster but faces pressure to confirm survival benefits. With neladalkib approved post-alectinib, your clinical strategy must emphasise durable response and brain metastases activity to compete.

◆ Coverage

1 source · 18 Nov 2026

◆ Related on Wire

◆ Topics

BiotechFDA-approvallung-cancerALK-inhibitorsaccelerated-approvaloncology-drugstargeted-therapy